These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 12044288)

  • 1. Novel agents for resistant Gram-positive infections--a review.
    Strahilevitz J; Rubinstein E
    Int J Infect Dis; 2002 Mar; 6 Suppl 1():S38-46. PubMed ID: 12044288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tedizolid: a new oxazolidinone antimicrobial.
    Kisgen JJ; Mansour H; Unger NR; Childs LM
    Am J Health Syst Pharm; 2014 Apr; 71(8):621-33. PubMed ID: 24688035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linezolid: a review of its use in the management of serious gram-positive infections.
    Perry CM; Jarvis B
    Drugs; 2001; 61(4):525-51. PubMed ID: 11324682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future trends in the treatment of serious Gram-positive infections.
    Metzger R; Bonatti H; Sawyer R
    Drugs Today (Barc); 2009 Jan; 45(1):33-45. PubMed ID: 19271030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.
    Cornaglia G; Rossolini GM
    Clin Microbiol Infect; 2009 Mar; 15(3):218-23. PubMed ID: 19335369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daptomycin - a novel antibiotic against Gram-positive pathogens.
    LaPlante KL; Rybak MJ
    Expert Opin Pharmacother; 2004 Nov; 5(11):2321-31. PubMed ID: 15500379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial-resistant gram-positive bacteria in PD peritonitis and the newer antibiotics used to treat them.
    Salzer W
    Perit Dial Int; 2005; 25(4):313-9. PubMed ID: 16022084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel antibacterial agents for the treatment of serious Gram-positive infections.
    Abbanat D; Macielag M; Bush K
    Expert Opin Investig Drugs; 2003 Mar; 12(3):379-99. PubMed ID: 12605562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of linezolid versus comparator therapies in Gram-positive infections.
    Wilcox MH
    J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii27-35. PubMed ID: 12730140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel antimicrobial agents against multi-drug-resistant gram-positive bacteria: an overview.
    Giannakaki V; Miyakis S
    Recent Pat Antiinfect Drug Discov; 2012 Dec; 7(3):182-8. PubMed ID: 23016758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomics of treatment with the newer anti-Gram-positive agents.
    Wang L; Barrett JF
    Expert Opin Pharmacother; 2006 May; 7(7):885-97. PubMed ID: 16634711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
    Napolitano LM
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fighting infections due to multidrug-resistant Gram-positive pathogens.
    Cornaglia G
    Clin Microbiol Infect; 2009 Mar; 15(3):209-11. PubMed ID: 19335367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: the shock of the new.
    David MZ; Dryden M; Gottlieb T; Tattevin P; Gould IM
    Int J Antimicrob Agents; 2017 Sep; 50(3):303-307. PubMed ID: 28666751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.
    Jones RN; Low DE; Pfaller MA
    Diagn Microbiol Infect Dis; 1999 Feb; 33(2):101-12. PubMed ID: 10091033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel pharmaceutical molecules against emerging resistant gram-positive cocci.
    Manfredi R; Sabbatani S
    Braz J Infect Dis; 2010; 14(1):96-108. PubMed ID: 20428664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial resistance trends among 5608 clinical Gram-positive isolates in China: results from the Gram-Positive Cocci Resistance Surveillance program (2005-2010).
    Zhao C; Sun H; Wang H; Liu Y; Hu B; Yu Y; Sun Z; Chu Y; Cao B; Liao K; Lei J; Hu Z; Zhang L; Zhang X; Xu Y; Wang Z; Chen M
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):174-81. PubMed ID: 22521693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of action of newer antibiotics for Gram-positive pathogens.
    Hancock RE
    Lancet Infect Dis; 2005 Apr; 5(4):209-18. PubMed ID: 15792738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.